BrightSpire Q2 Earnings Beat 16%

BrightSpire Capital (BRSP) priced a $960M commercial real estate CLO, set to close October 16. The deal includes 29 mortgages secured by 38 properties, with $844.8M in investment-grade securities. The weighted-average coupon is Term SOFR plus 1.54%. BRSP plans to redeem its BRSP 2024-FL2 securitization on October 19. The transaction aims to improve funding efficiency and flexibility, but risks include credit exposure and floating-rate mortgage challenges.

BrightSpire Capital, Inc. (BRSP) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 BRIGHTSPIRE CAPITAL, INC. Introduction to Unaudited Pro Forma Condensed Consolidated Financial Statements Introductory Note On June 12, 2026, the Sellers entered into the Purchase and Sale Agreement with the Purchasers, pursuant to which the Purchasers agreed to acqu

BrightSpire Capital, Inc. (BRSP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 q226earningssupplement07.htm EX-99.2 q226earningssupplement07 1 JULY 28, 2026 SUPPLEMENTAL FINANCIAL REPORT SECOND QUARTER 2026 Exhibit 99.2 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation may contain forward-looking statements within the m

D.A. Davidson analyst Gil Luria raised Micron's (MU) price target to $3,000, citing a 3-5 year growth trajectory driven by AI demand. He argues memory is now a 'mission-critical' component, with long-term supply agreements reducing cyclicality. Micron's Q4 sales surged to $54.23B, with strong guidance and increased long-term commitments. Bank of America also raised its revenue estimates, but differs on valuation. MU trades at 5.94x forward earnings, below sector median.

Cipher Digital (NASDAQ:CIFR) shares rose 0.55% to $14.64 in after-hours trading. Bitfury's Top HoldCo delivered 1.84M shares as part of a forward contract, per SEC filings. Top HoldCo holds 6.2% of Cipher's shares, with V3 Holding and Valerijs Vavilovs owning 13.2%. CIFR's market cap is $6.04B, with a 52-week range of $11.72-$30.14.

Argus lowered its target price for PTC Therapeutics (PTCT) to $61.00, maintaining a HOLD rating. The company has medium ratings for industry, management, and growth, but low ratings for safety and value.